학술논문
Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM).
Document Type
Academic Journal
Author
Brož J; Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic. zorb@seznam.cz.; Janíčková Žďárská D; Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic.; Urbanová J; Center for Research in Diabetes, Metabolism and Nutrition, 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic.; Brabec M; Institute of Computer Science of the ASCR, v.v.i., Prague, Czech Republic.; Czech Institute of Informatics, Robotics, and Cybernetics, Czech Technical in University, Prague, Czech Republic.; Doničová V; Private Department of Diabetology Internal Medicine and Metabolism, Kosice, Slovakia.; Štěpánová R; Aprova sro, Brno, Czech Republic.; Martinka E; National Institute of Endocrinology and Diabetology, Lubochna, Slovakia.; Kvapil M; Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic.
Source
Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1869-6953
Abstract
Introduction: The aim of the study was to determine the level of metabolic control in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients in the Czech and Slovak Republics.
Methods: A non-interventional prospective (observational) study was conducted from January 2015 until April 2016 in routine clinical practice settings at 141 centers in the Czech and Slovak Republics. Data were analyzed from a total of 425 patients with T1DM and 1034 patients with T2DM, proportionally corresponding to the number of patients in both countries. The primary objective of the study was to determine the percentage of patients with HbA1c < 7% (53 mmol/mol).
Results: Patients with T1DM: In this group of patients (55.8% males, mean age 45.9 ± 14.83 years, BMI 25.8 ± 4.21 kg/m², diabetes duration 12.1 ± 9.44 years), 29.9% reached HbA1c levels < 53 mmol/mol. Patients with T2DM: In this group of patients (50.3% male, mean age 63.9 ± 9.65 years, BMI 31.0 ± 5.19 kg/m², diabetes duration 12.4 ± 7.47 years, duration of insulin therapy 5.8 ± 4.71 years), 33.4% reached HbA1c levels < 53 mmol/mol.
Conclusion: The overall percentage of patients with HbA1c < 53 mmol/mol in the T1DM group was 29.9% and in the T2DM group was 33.4%. Despite an increasing number of treatment options, most patients still fail to reach the recommended HbA1c targets.
Funding: Sanofi, Czech Republic.
Methods: A non-interventional prospective (observational) study was conducted from January 2015 until April 2016 in routine clinical practice settings at 141 centers in the Czech and Slovak Republics. Data were analyzed from a total of 425 patients with T1DM and 1034 patients with T2DM, proportionally corresponding to the number of patients in both countries. The primary objective of the study was to determine the percentage of patients with HbA1c < 7% (53 mmol/mol).
Results: Patients with T1DM: In this group of patients (55.8% males, mean age 45.9 ± 14.83 years, BMI 25.8 ± 4.21 kg/m², diabetes duration 12.1 ± 9.44 years), 29.9% reached HbA1c levels < 53 mmol/mol. Patients with T2DM: In this group of patients (50.3% male, mean age 63.9 ± 9.65 years, BMI 31.0 ± 5.19 kg/m², diabetes duration 12.4 ± 7.47 years, duration of insulin therapy 5.8 ± 4.71 years), 33.4% reached HbA1c levels < 53 mmol/mol.
Conclusion: The overall percentage of patients with HbA1c < 53 mmol/mol in the T1DM group was 29.9% and in the T2DM group was 33.4%. Despite an increasing number of treatment options, most patients still fail to reach the recommended HbA1c targets.
Funding: Sanofi, Czech Republic.